Navigation Links
New Drug May Help Fight Certain Advanced Lung Cancers
Date:6/3/2013

MONDAY, June 3 (HealthDay News) -- For patients struggling with a common and deadly form of lung cancer, adding the drug ganetespib to a standard chemotherapy drug may boost survival, new research suggests.

The finding centers on a class of medications known as heat shock protein 90 (Hsp90) inhibitors, and it's the first time in more than 10 years that researchers have uncovered a better way to treat this group of patients.

The findings were slated for presentation Monday in Chicago at the annual meeting of the American Society of Clinical Oncology.

"This is the first randomized study to demonstrate therapeutic benefit with a heat shock protein inhibitor in patients with cancer," study lead author Dr. Suresh Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, in Atlanta, said in an ASCO news release.

The study focused on patients with a form of non-small cell lung cancer known as lung adenocarcinoma.

"We hope that the ongoing study will confirm our findings, as patients with this common form and stage of lung cancer urgently need more effective treatments," Ramalingam said.

The researchers said adenocarcinoma is the most common form of lung cancer. In the United States, it accounts for roughly 45 percent of the 170,000 non-small cell lung cancers diagnosed annually.

Ganetespib works by halting the function of newly established proteins that are involved in promoting the lung tumor's growth.

The new study was funded by drug maker Synta Pharmaceuticals and involved more than 250 patients, all of whom had tried standard treatments to no avail.

Half the patients were treated with the standard chemotherapy drug docetaxel, while the other half were given ganetespib in tandem with docetaxel.

Patients in the ganetespib group had longer average survival rates relative to those in the docetaxel-only group -- 9.8 months versus 7.4 months, respectively. Patients with advanced cancer that had been diagnosed at least six months prior to treatment saw a 67 percent boost in survival compared to similar patients who didn't get the new drug.

The researchers noted that prior trials on Hsp90 inhibitor drugs haven't panned out because side effects for patients were so dire. They said this is the first trial in which the drug has proven both safe and potentially effective.

Experts who weren't involved in the research were encouraged by the results.

"Ganetespib, in combination with docetaxel, shows promising early results in lung adenocarcinoma," Dr. Marjorie Zauderer, an ASCO spokeswoman and lung cancer expert, said in the news release. "We're hopeful about the outcome of an ongoing study, which could help more patients with this form of advanced lung cancer access this promising drug."

Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, agreed.

"Finally there is a drug that can be offered to patients with advanced lung cancer, along with another drug," Horovitz said. "Ganetespib appears to increase overall survival independent of genetic markers. Since so many lung cancers are diagnosed at a late stage, this may help many patients."

Findings presented at medical meetings typically are considered preliminary until published in a peer-reviewed journal.

More information

For more on lung cancer, head to the U.S. National Cancer Institute.

-- Alan Mozes

SOURCES: June 3, 2013, news release, American Society of Clinical Oncology; Len Horovitz, M.D, pulmonary specialist, Lenox Hill Hospital, New York City


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. National Camp Series (NCS) Associate Chris Husby Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer
2. Stress Kills (Literally), But It’s Not Too Late to Fight Back
3. Researchers discover new weapon in fight against cervical cancer
4. Immune system to fight brain tumors
5. Sport-Social for Autism Fights to Win Contest
6. Sailormen Inc. Popeyes Raises More than $670,000 to Help Fight Muscle Disease
7. Retired NFL Kicker and National Camp Series (NCS) Founder Michael Husted Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer
8. Austin Sports Medicine Presents: Five Tips for Fighting Childhood Obesity
9. Common Supplement May Help Patients Fight Heart Failure
10. Modified Polio Virus May Help Fight Brain Tumors, Study Suggests
11. When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Help Fight Certain Advanced Lung Cancers
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: